Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond

T-DM1 represents a prototypic ADC, being one out of the four ADCs approved by the FDA for clinical use, and the only one indicated for advanced HER2-positive breast cancer, becoming a pillar of targeted therapy in this disease. Recently, T-DM1 has gained FDA approval as an adjuvant treatment option for patients with HER2-positive early breast cancer following neoadjuvant treatment with trastuzumab and chemotherapy. Resistance to the action of...